Anazales, 1 mg 28 pcs.

Antitumor agent. It is a selective non-steroidal aromatase inhibitor. In postmenopause estradiol is mainly formed from estrone, which is produced in peripheral tissues by conversion from androstenedione (with the participation of aromatase enzyme). Reducing circulating estradiol levels has a therapeutic effect in women with breast cancer. In postmenopause, anastrozole at a daily dose of 1 mg causes a decrease in estradiol levels by 80%. Anastrozole has no progestogenic, androgenic and estrogenic activity; in therapeutic doses it does not affect cortisol and aldosterone secretion.

Pharmacokinetics

Indications

Cancer, NoBreast Cancer in Postmenopause.

Active ingredient

Anastrozole

Composition

White, round, biconvex, film-coated tablets with “ANA 1” engraved on one side of the tablet; white or almost white on the fracture.

Associates:

Lactose monohydrate,

povidone,

sodium carboxymethyl starch,

magnesium stearate.

Film coating:

Opadray white (macrogol 400, hypromellose, titanium dioxide).

How to take, the dosage

Orally – 1 mg once a day.

Interaction

Anastrozole reduces the effectiveness of estrogens.

Clinical studies have shown that simultaneous use of anastrozole with antipyrine and cimetidine drug interaction due to induction of microsomal liver enzymes is unlikely.

Special Instructions

If the hormonal status of the patient is uncertain, the menopausal state should be confirmed by additional biochemical studies.

The safety of anastrozole administration in patients with moderate liver function abnormalities has not been established.

Anastrozole should not be used concomitantly with estrogens.

Effect on driving and operating machinery

During treatment, do not perform work requiring high concentration and rapid psychomotor reactions.

Contraindications

Premenopause, severe renal insufficiency (CKR less than 20 ml/min), moderate and severe hepatic insufficiency, pregnancy, lactation, childhood, hypersensitivity to anastrozole.

Side effects

Endocrine system: “hot flashes”, vaginal dryness and thinning of hair.

Digestive system: anorexia, nausea, vomiting, diarrhea. In patients with advanced breast cancer, in most cases with metastases to the liver, elevated levels of GGT and rarely – alkaline phosphate were noted.

CNS: asthenia, somnolence, headache.

Metabolism: a slight increase in total cholesterol.

Allergic reactions: skin rash.